Compositions and methods for modulating ischemic injury

Abstract

The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents.

What is claimed is: 
     
         1 . A method for modulating ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising Inflammatory Response Modulating Cells (IRMCs), a composition comprising IRMC membranes, and a composition comprising a combination of both IRMCs and IRMC membranes. 
     
     
         2 . A method for reducing ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising IRMCs, a composition comprising IRMC membranes, and a composition comprising a combination of both IRMCs and IRMC membranes. 
     
     
         3 . A method for increasing the time to ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising IRMCs, a composition comprising IRMC membranes, and a composition comprising a combination of both IRMCs and IRMC membranes. 
     
     
         4 . The method of any one of  claim 1 ,  2 , or  3  wherein the IRMCs are selected from the group consisting of extraembryonic (EE) cells, extraembryonic HLA-G positive (EHP cells), Amnion-derived Multipotent Progenitor (AMP) cells, Mesenchymal Stem Cells (MSC), Sertoli cells, hepatic stellate cells, adult basal fibroblasts, donor matched unseparated bone marrow cells, donor matched splenocytes, embryonic stem cells (ES cells), hematopoietic stem cells (HSCs) and certain regulatory T cells (Tregs) and wherein the IRMC membranes are selected from the group consisting of EE cell, EHP cell, AMP cell, MSC, Sertoli cell, Hepatic Stellate cell, adult basal fibroblasts, donor matched unseparated bone marrow cells, donor matched splenocyte, embryonic stem cell (ES cell), hematopoietic stem cell (HSC) and certain regulatory T cell (Treg) membranes. 
     
     
         5 . The method of any one of  claim 1 ,  2 , or  3  wherein the IRMCs are AMP cells and the IRMC membranes are AMP cell membranes. 
     
     
         6 . The method of  claim 4  wherein the cells are irradiated prior to use. 
     
     
         7 . The method of  claim 4  wherein the cells are cultured under hypoxic conditions prior to use. 
     
     
         8 . The method of any one of  claim 1 ,  2 , or  3  wherein the IRMCs or IRMC membranes are perfused in combination with another active agent, wherein the other agent is selected from the group consisting of corticosteroids, cyclosporine, tacrolimus, sirolimus, methotrexate, azathiopine, mercatopurine, cytotoxic antibiotics, polyclonal antibodies, monoclonal antibodies, interferon, opioids, TNF binding proteins, mycophenolate, FTY720 and other cell types.